Immunovant, Inc. (IMVT)

Immunovant Statistics

Total Valuation

Immunovant has a market cap or net worth of $2.78 billion. The enterprise value is $2.07 billion.

Market Cap	2.78B
Enterprise Value	2.07B

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025, after market close.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunovant has 170.92 million shares outstanding. The number of shares has increased by 9.76% in one year.

Current Share Class	170.92M
Shares Outstanding	170.92M
Shares Change (YoY)	+9.76%
Shares Change (QoQ)	+13.48%
Owned by Insiders (%)	0.89%
Owned by Institutions (%)	50.16%
Float	63.26M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.92
P/TBV Ratio	3.94
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 11.16, with a Debt / Equity ratio of 0.00.

Current Ratio	11.16
Quick Ratio	10.42
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -62.46% and return on invested capital (ROIC) is -41.32%.

Return on Equity (ROE)	-62.46%
Return on Assets (ROA)	-37.97%
Return on Invested Capital (ROIC)	-41.32%
Return on Capital Employed (ROCE)	-61.93%
Revenue Per Employee	n/a
Profits Per Employee	-$1.14M
Employee Count	362
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immunovant has paid $891,000 in taxes.

Income Tax	891,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.28% in the last 52 weeks. The beta is 0.61, so Immunovant's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	-35.28%
50-Day Moving Average	15.01
200-Day Moving Average	23.16
Relative Strength Index (RSI)	60.20
Average Volume (20 Days)	1,175,131

Short Selling Information

The latest short interest is 21.40 million, so 12.52% of the outstanding shares have been sold short.

Short Interest	21.40M
Short Previous Month	20.71M
Short % of Shares Out	12.52%
Short % of Float	33.83%
Short Ratio (days to cover)	16.24

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-438.15M
Pretax Income	-271.89M
Net Income	-413.84M
EBITDA	-437.78M
EBIT	-438.15M
Earnings Per Share (EPS)	-$2.73

Balance Sheet

The company has $713.97 million in cash and $98,000 in debt, giving a net cash position of $713.87 million or $4.18 per share.

Cash & Cash Equivalents	713.97M
Total Debt	98,000
Net Cash	713.87M
Net Cash Per Share	$4.18
Equity (Book Value)	707.45M
Book Value Per Share	4.16
Working Capital	698.89M

Cash Flow

In the last 12 months, operating cash flow was -$375.87 million and capital expenditures -$759,000, giving a free cash flow of -$376.63 million.

Operating Cash Flow	-375.87M
Capital Expenditures	-759,000
Free Cash Flow	-376.63M
FCF Per Share	-$2.20

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovant does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-9.76%
Shareholder Yield	-9.76%
Earnings Yield	-14.86%
FCF Yield	-13.53%

Analyst Forecast

The average price target for Immunovant is $40.14, which is 146.41% higher than the current price. The consensus rating is "Buy".

Price Target	$40.14
Price Target Difference	146.41%
Analyst Consensus	Buy
Analyst Count	10
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1